Clinical trials: Antipsychotics
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Obesity
Metformin for Weight Loss in Schizophrenia
Study hypothesis is that patients on antipsychotics medication treated with metformin will show loss in weight and improved measures of glucose metabolism.
- Trial name
- NCT01177709
- Testing
- Metformin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Diabetes, Obesity
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
This program aims to help Veterans who take antipsychotic medications lose weight. The investigators use a program based on the American Diabetes Association's "Diabetes Prevention Program," and the investigators have modified it…
- Conditions
- Diabetes, Obesity, Weight Gain
- Trial name
- MAMAO (NCT00344500)
- Testing
- Behavioral Weight Loss Program
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- VA Office of Research and Development
Delirium, Impaired Cognition
The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study
The long-term objective of the MIND-USA (Modifying the Impact of ICU-Induced Neurological Dysfunction-USA) Study is to define the role of antipsychotics in the management of delirium in vulnerable critically ill patients.
- Conditions
- Delirium, Impaired Cognition, Long Term Psychologic Disorders
- Trial name
- MIND-USA (NCT01211522)
- Testing
- Haloperidol, Ziprasidone
- Where
- 16 sites in United States
- Volunteers
- 566 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
The purpose of this study is to determine whether calcium and vitamin D supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia.
- Trial name
- NCT00799383
- Testing
- Calcium and Vitamin D
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Chadi A. Calarge
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Obesity, Vitamin D Deficiency
Vitamin D Supplementation in Psychiatric Illnesses
Children and adolescents with psychiatric illnesses who are treated with medications called second generation antipsychotic agents (SGA) often gain excessive weight during their treatment with these medications.
- Conditions
- Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia
- Trial name
- VDSS (NCT01004354)
- Testing
- Ergocalciferols
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
Antipsychotic Effects of Oxytocin
The objective of the study is to compare the efficacy of intranasal oxytocin versus intranasal placebo to improve symptoms in schizophrenia patients who have residual symptoms despite being on adequate treatment with…
- Trial name
- NCT01621737
- Testing
- Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of California, San Diego
Alzheimer Disease, Dementia Alzheimers
An Electronic Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions
The goal of this study will be to design, implement and test the impact of a quality improvement (QI) intervention that uses an EHR CDS tool among physicians newly ordering an antipsychotic medication for older adults with ADRD.
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia of Alzheimer Type
- Trial name
- NCT04851691
- Testing
- EHR CDS, Usual Care
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- University of California, Los Angeles
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
The purpose of this study is to evaluate the long-term treatment efficacy, and safety of risperidone long-acting injection in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT01894984
- Testing
- Risperidone, Oral atypical anti-psychotic
- Volunteers
- 640 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been…
- Trial name
- NCT01157351
- Testing
- paliperidone, risperidone, haloperidole
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 450 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia
Safety and Efficacy of Cariprazine in Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104779
- Testing
- Cariprazine
- Where
- 41 sites in United States, Colombia and 2 more
- Volunteers
- 446 people
- Sponsor
- Forest Laboratories
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
This study will test the safety of an aripiprazole injection in subjects with schizophrenia that are currently taking oral antipsychotic medication other than aripiprazole.
- Trial name
- NCT01552772
- Testing
- Aripiprazole IM Depot
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of different dosages (from 3 mg/day to 12 mg/day) of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute…
- Trial name
- NCT00412373
- Testing
- Paliperidone ER
- Where
- 44 sites in United States, India and 4 more
- Volunteers
- 307 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.